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Abstract
Purpose Human alveolar (AE) and cystic echinococcosis
(CE) caused by the metacestode stages of Echinococcus
multilocularis and E. granulosus, respectively, lack
pathognomonic clinical signs. Diagnosis therefore relies on
the results of imaging and serological studies. The primary
goal of this study was to evaluate the efficacy of several
easy-to-produce crude or partially purified E. granulosus
and E. multilocularis metacestode-derived antigens as tools
for the serological diagnosis and differential diagnosis of
patients suspicious for AE or CE.
Methods The sera of 51 treatment-naı¨ve AE and 32 CE
patients, 98 Swiss blood donors and 38 patients who were
initially suspicious for echinococcosis but suffering from
various other liver diseases (e.g., liver neoplasia, etc.) were
analysed.
Results According to the results of enzyme-linked
immunosorbent assays (ELISA), metacestode-derived
antigens of E. granulosus had sensitivities varying from 81
to 97% and [99.9% for the diagnosis of CE and AE,
respectively. Antigens derived from E. multilocularis
metacestodes had sensitivities ranging from 84 to 91% and
[99.9% for the diagnosis of CE and AE, respectively.
Specificities ranged from 92 to [99.9%. Post-test
probabilities for the differential diagnosis of AE from liver
neoplasias, CE from cystic liver lesions, and screening for
AE in Switzerland were around 95, 86 and 2.2%, respec-
tively. Cross-reactions with antibodies in sera of patients
with other parasitic affections (fasciolosis, schistosomosis,
amebosis, cysticercosis, and filarioses) did occur at vari-
able frequencies, but could be eliminated through the use
of confirmatory testing.
Conclusions Different metacestode-derived antigens of
E. granulosus and E. multilocularis are valuable, widely
accessible, and cost-efficient tools for the serological
diagnosis of echinococcosis. However, confirmatory test-
ing is necessary, due to the lack of species specificity and
the occurrence of cross-reactions to other helminthic
diseases.
Keywords Echinococcosis  Diagnosis  Serology 
Metacestode
Introduction
Human alveolar (AE) and cystic echinococcosis (CE) are
caused by the metacestode (larval) stages of the fox tape-
worm Echinococcus multilocularis and the dog tapeworm
Echinococcus granulosus, respectively. Humans are
infected by orally ingesting viable parasite eggs. Endemic
areas for AE are restricted to the temperate and arctic
regions of the northern hemisphere, and the disease is
widespread in parts of Central Europe, Asia, and North
America [1]. The liver is the most common site of AE
lesions, and the parasite behaves in a way similar to a
malignant tumour, showing both local invasive and meta-
static growth, although the growth rate is much slower than
in neoplasia. The treatment of AE is based on surgery in
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combination with anthelminthic treatment for at least
2 years or, in inoperable cases, on lifelong chemotherapy
[2]. Untreated, mortality is high with a 10- and 15-year
survival rate of 29 and 0%, respectively [3]. However, with
state-of-the-art treatment, prognosis is favourable, and the
life expectancy of patients is almost normal [4]. In contrast,
CE occurs almost worldwide, except for some regions of
Central Europe and North America. In addition to the liver,
the lungs and bones are also frequently involved in the
disease. Unlike in AE, the parasite shows no invasive
behaviour but grows as a clearly demarcated space-occu-
pying lesion. However, spreading may occur after the
spontaneous, traumatic or iatrogenic rupture of cysts (e.g.
intraperitoneal). Growth of the cysts mainly leads to
compression of the organs affected and may interfere with
organ function leading to unspecific symptoms. Also, CE
does not inevitably lead to death if left untreated [5].
Treatment is based on surgery or other invasive methods in
combination with anthelminthic treatment that is aimed at
the total eradication of viable parasite material [2].
Several recent reports suggest that incidences and
prevalences of AE and CE are increasing in various parts of
the world. For example, in Switzerland, the incidence of
AE increased more than twofold from 2001–2005 com-
pared to previous years (1993–2000: mean incidence 0.10
cases/100,000 inhabitants per year; 2001–2005: 0.26 cases/
100,000 inhabitants per year [6]). In Lithuania, there were
10–16 reported AE cases/year in 2002–2006 compared
with 0–4 cases/year in 1997–2001 [7]. Several reports have
also highlighted increasing numbers of cases in Asia. In
Kyrgyzstan, the incidence of CE has increased from 5.4 in
1991 to 18 in 2000 [8]. Several regions endemic for CE as
well as AE have been recognised in north-western, central
and north-eastern China, and AE has also spread to the
Japanese island of Hokkaido in the last decades [9, 10].
As AE and CE have no pathognomonic features, their
diagnosis relies heavily on the results of imaging studies
and serological methods [2]. Current guidelines for the
diagnosis of AE and CE are primarily based on clinical and
epidemiological findings compatible with AE/CE. In
addition, definitions of cases are based on the results of
species-specific serological tests and imaging studies, with
positive results of either one enabling a possible diagnosis
of AE/CE, and positive results for both allowing a probable
diagnosis of AE/CE. The gold standard for confirmation of
cases is histopathological evaluation and/or the detection of
parasite-specific DNA or parasite material (e.g. protos-
coleces in CE) in bioptic samples [2].
The most widely used antigens for the serological
diagnosis of AE and CE are crude or partially purified
native antigens isolated from metacestode stages of both
species. A number of recombinant antigens have also been
developed, but their use in standard diagnostic laboratories
is limited [11]. Immunofluorescence antibody tests (IFAT),
based on protoscoleces of E. granulosus, have been in use
since 1967 [12] and can have diagnostic sensitivities of
[95% in hepatic CE but suffer from relatively poor spec-
ificities [2].
The protoscolex-derived antigens of E. multilocularis
as well as E. granulosus, which are used in enzyme-
linked immunosorbent assays (ELISA) or immunoblots,
have also been studied. Auer et al. [13] described the
value of antigens derived from supernatants of E. multi-
locularis protoscoleces maintained in vitro. In immuno-
blot assays, these antigens showed no cross-reactivity to
sera of patients suffering from cysticercosis, schistoso-
mosis or fasciolosis and were even able to differentiate
AE from CE in all 40 cases studied [13]. In two other
studies, affinity-purified E. multilocularis metacestode
antigens Em2 or Em2(G11) [14, 15] showed substantially
improved species specificities of [95% and allowed the
serological identification of AE in a considerable number
of cases.
Common crude antigens derived from E. multilocularis
metacestode material, including protoscoleces, contain
various amounts of Em2, a very immunogenic compound
of metacestode tissue (mainly from the laminated layer of
cyst walls) [15, 16]. To assess the diagnostic performance
of novel, more standardised antigens, removal of Em2 and
cyst wall material is mandatory.
As native antigen, cyst fluid contains numerous lipo-
and glycoproteins, salts, carbohydrates and lipids, as well
as some components derived from the host, such as
albumin and immunoglobulins; consequently, the com-
position of these antigens is subject to variability
depending on the stage of the cyst as well as the corre-
sponding host [17–19]. Thus, differences in diagnostic
performance in terms of sensitivity, specificity and cross-
reactivity have to be expected. Nevertheless, a compara-
tive analysis by Lorenzo [20] and colleagues of the
diagnostic potential of EgHF from six different batches
applied on the same sera displayed differences in the
intensity of the reaction, but there was no impact on the
diagnostic parameters.
In contrast, the composition of purified protoscoleces is
likely to be less dependent on the stage of cysts and con-
tains fewer host-derived-proteins, theoretically, therefore
yielding a higher reproducibility of results as a step
towards further standardisation of the serological diagnosis
of echinococcosis.
The aim of the this study was to evaluate the diagnostic
value of different crude and partially purified native
E. multilocularis- and E. granulosus-derived antigens,
which can be prepared without sophisticated technical
equipment and to assess their diagnostic potential in dif-
ferent defined clinical settings.
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Materials and methods
Sera
Fifty-one sera of treatment-naı¨ve AE patients (sample
taken prior to treatment initiation) from the University
Hospital of Zurich (USZ) Echinococcosis Cohort as well
as 32 sera from CE patients (29 treatment-naı¨ve, three
relapses) were used. Diagnosis was achieved in all
patients according to the World Health Organisation
(WHO) criteria [2]. Sera of clinically and/or parasitolog-
ically diagnosed patients suffering from amoebic liver
abscess (19 patients), cysticercosis (19), fasciolosis (16),
filarioses (8) and schistosomosis (18) were used for the
evaluation of cross-reactions. Cut-off values were deter-
mined using sera of 98 Swiss blood donors. Thirty-eight
sera of patients with other pathologies affecting the liver
but an initial clinical suspicion for echinococcosis from
the USZ Department of Gastroenterology (16 liver cysts,
2 hepatitis cases, 13 neoplasias, 1 sarcoidosis, 1 peliosis
hepatis, 1 sclerosing cholangitis, 1 liver cirrhosis and 3
unknown causes despite extensive clinical evaluation)
were used in the evaluation of specificities and likelihood
ratios.
Patient characteristics
AE patients
Of the 51 treatment-naı¨ve AE patients, 29 were female and
22 were male; the average age was 54 ± 16 years. Most
patients were of Swiss nationality (48/51). Three patients
had immigrated into Switzerland more than 24 years pre-
viously. The liver was involved in all patients, and seven
patients had involvement of other organs [lung (3), dia-
phragm (2), spleen (1), adrenal gland (1), kidney (1),
intraperitoneal (1)].
CE patients
Of the 32 CE patients, ten were female and 22 were male;
the average age was 35 ± 15 years. Most patients origi-
nated from the Balkans [Macedonia (6 patients), Kosovo
(2), Albania (1), Montenegro (1)]. It was not possible to
determine the exact allocation of three other patients
originally from countries of the former Yugoslavia. Eight
patients were from Turkey, two each were from Portugal
and Italy, and one each was from Iraq and Uruguay. Only
five patients had lived in Switzerland all of their life, and
two of these had near relatives in Kosovo. Cysts were
localised in the liver (20 patients), liver and lung (2), liver
and peritoneal cavity (2), liver and bone (1), lung (1),
skeleton (3) and abdomen (3).
Liver cysts were classified according to the WHO
classification system [21] based on ultrasound (US) find-
ings as follows: CE1 (4 patients), CE2 (4), CE3 (5), CE5
(3) and extrahepatic (7); the results of imaging studies were
not available for nine patients.
Parasite isolates
Echinococcus multilocularis metacestode tissue (isolate
IPZ CH Hd2, derived from a Swiss dog) was maintained in
gerbils (Meriones unguiculatus) by repetitive intraperito-
neal transplantation, as described elsewhere [22]. For
preparation of E. multilocularis vesicular fluid, metaces-
tode tissue was cultivated in vitro, resulting in the forma-
tion of metacestode vesicles, as described by Mu¨ller and
colleagues [23]. Fertile E. granulosus cysts were collected
from sheep in Kyrgyzstan. An overview of the parasite
isolates used and important steps in the production of the
different antigens is given in Table 1.
Preparation of cyst fluid antigens (EmVF, EgHF)
Echinococcus multilocularis metacestode vesicles were
harvested from in vitro cultures, washed three times in
phosphate buffered saline (PBS) and sliced. Vesicle fluid in
PBS was used as the antigen (EmVF). For preparation of
E. granulosus hydatid fluid (EgHF) antigens, fluid from
fertile cysts was aspirated. Both the aspirate and harvested
vesicle fluid were centrifuged at 14,000 g for 20 min at 4C
and then dialysed against PBS for 48 h.
Preparation of cyst/Em2-depleted E. multilocularis
protoscolex antigen (EmP)
Echinococcus multilocularis metacestode material was
mechanically reduced to small pieces and repetively
washed in PBS. After passage through a 150-lm sieve as
a first purification step, protoscoleces were retained in an
80-lm sieve [29], washed twice in PBS and further
purified from small cysts and debris of the laminated
layer containing the Em2-antigen using magnetic beads
(Dynabeads; Rat anti-Mouse IgG1; Invitrogen Dynal AS,
Oslo, Norway) loaded with monoclonal antibodies spe-
cific for Em2 (mAb Em2G11) [15]. In brief, 25 ll of
Dynabeads were washed twice in PBS, following which
7.5 ll of mAb Em2G11 was added and the Dynabeads/
mAb Em2G11 incubated at room temperature for 30 min.
This was followed by the addition of 1 ml of a protos-
colex solution and further incubation on ice for 30 min.
After separation in a magnetic field for 2 min, cyst-
depleted protoscoleces were harvested from the superna-
tant. The EmP antigen was prepared as described for
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E. granulosus protoscoleces. Cyst-depleted antigen at a
high concentration of 0.01 mg/ml gave negative results in
a mAb Em2G11-based sandwich ELISA [15].
Preparation of E. granulosus protoscolex antigens
(EgP)
Protoscoleces were harvested from cysts, sieved and
washed as described above, frozen/thawed three times in
liquid nitrogen and a water bath (37C). After ultrasoni-
cation and centrifugation (14,000g for 20 min at ?4C),
the supernatant containing soluble proteins was dialysed
against PBS and used as antigen.
Preparation of integument antigens (EmPI, EgPI)
Protoscoleces of E. granulosus and E. multilocularis (cyst/
Em2-depleted, as described above) were frozen at -20C
and thawed. After sedimentation for 5 min, the supernatant
was centrifuged at 14,000g for 3 min at 4C. Soluble
integument constituents in the supernatant were dialysed
against PBS for 48 h at 4C (EgPI, EmPI).
Preparation of E. multilocularis metacestode antigens
(EmC)
Metacestode material was collected from infected gerbils.
For preparation of crude antigen fractions the material was
homogenised in PBS with a disruptor prior to freezing/
thawing at -198C, ultrasonication (40%/30W/3 9 20 s.),
centrifugation (14,000g for 30 min at 4C) and dialysis
against PBS.
Defined antigens
Antigen B (AgB) was prepared as described elsewhere [24,
25], the Em2(G11) antigen was prepared as described by
Deplazes et al. [15], and the recombinant Em18 antigen
was provided by the Institute of Parasitology in Bern,
Switzerland [26, 27].
Enzyme-linked immunosorbent assay
All ELISA were performed in 96-well microtiter plates
(Nunc; Maxisorp, Roskilde, Denmark). Protein concentra-
tions were measured by the Bradford method (Bio-Rad
Protein Assay; Bio-Rad, Hercules CA). Optimal antigen
concentrations are known based on the results of previous
titration experiments (data not shown). Plates were coated
with the respective antigen in 0.1 M carbonate/bicarbonate
buffer (pH 9.6) containing 0.02% NaN3 and left standing
overnight at 4C. The plates were then washed four times
with physiological NaCl/0.3% Tween-20 (NaCl-T) and sat-
urated for 30 min at 37C with PBS (pH 7.2) containing
0.02% (w/v) NaN3, 0.05% (w/v) bovine haemoglobin and
0.3% (v/v) Tween-20 (PBS-T). A 100-ll aliquot of sera
diluted 1:200 in PBS-T was added per well and incubated for
1 h at 37C. The plates were then washed four times with
NaCl-T, and 100 ll of anti-human-immunoglobulin G (IgG;
polyclonal rabbit anti-human-IgG, specific for the CH2
domain; DAKO, Glostrup, Denmark) conjugated to alkaline
phosphatase (Roche Applied Science, Rotkreuz, Switzer-
land) at a dilution of 1:500 in PBS-T was added. After
incubation for 1 h at 37C, the plates were washed five times
(NaCl-T), and 100 ll per well of a 1 mg/ml solution of
Table 1 Overview of primary materials and antigen preparation processes of crude or partially purified native antigens
Antigen Primary material Species and morphological correlate Preparation
EgHF Hydatid cyst, sheep Echinococcus granulosus cyst fluid Centrifugation, dialysis
EgP Hydatid cyst, sheep E. granulosus whole protoscolex Freezing at -198C, thawing, ultrasonication,
centrifugation, dialysis
EgPI Hydatid cyst, sheep E. granulosus protoscolex integument Freezing at -20C, thawing, sedimentation
centrifugation, dialysis
EmVF Echinococcus multilocularis
metacestode cultivated in vitro
E. multilocularis vesicular fluid Cutting, centrifugation, dialysis
EmP E. multilocularis metacestode
grown in gerbils
E. multilocularis whole protoscolex;
Em2/cyst wall-depleted
Harvesting of protoscoleces by sieving; cyst-
depletion by mAb Em2G11
Freezing at -198C, thawing, ultrasonication,
centrifugation, dialysis
EmPI E. multilocularis metacestode
grown in gerbils
E. multilocularis protoscolex
integument; Em2/cyst wall-depleted
Harvesting of protoscoleces by sieving; Em2-
depletion by mAb Em2G11
Freezing at -20C, thawing, centrifugation, dialysis
EmC E. multilocularis metacestode
grown in gerbils
E. multilocularis whole metacestode Freezing at -198C, thawing, homogenisation,
ultrasonication, centrifugation, dialysis
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p-nitrophenyl phosphate disodium salt hexahydrate (cat. no.
71768; Sigma, St. Louis, MO) in 0.05 M carbonate/bicar-
bonate buffer (pH 9.8) containing 1 mM MgCl2 was added.
Absorbance values were read at 405 nm (OD405) with a
reference wavelength of 630 nm. Positive standard sera of
human patients with parasitologically proven AE or CE and
negative standard sera of blood donors were included in all
test runs. For the determination of cut-off-values, receiver-
operator-curve (ROC) analyses were performed [28]. For all
antigens, except the species-specific antigens Em2G11 and
Em18, Swiss blood donors were defined as negative sera,
whereas sera of AE and CE patients were defined as positive
sera. For the Em2G11 and Em18 antigens, Swiss blood
donors and CE patients were taken as negative sera and AE
patients as positive sera. Cut-off values were set at the OD405
corresponding to the maximum Youden Index (defined as:
sensitivity ? specificity - 1) [29].
Immunoelectrotransfer blot
Confirmatory tests for CE by AgB enzyme-linked immu-
noelectrotransfer blot (AgB-EITB) were performed as
described elsewhere [24].
Evaluation of test performances
Sensitivities for all antigens were evaluated in terms of
their efficacy in the serological diagnosis of AE or CE.
Specificities were evaluated for Swiss blood donors and
patients with non-parasitic liver lesions or parasitic
infections.
Likelihood ratios and post-test probabilities (reviewed in
[30]) were calculated for different clinical and epidemio-
logical settings:
1. Differential diagnosis of AE from liver neoplasias
(Swiss patients). The prevalence of AE among all
patients presenting with imaging studies compatible
with liver neoplasia or AE was assumed to be 1.5%:
AE incidence in Switzerland (0.26, [6]) divided by the
incidence of the most common primary liver cancer
cases (cholangiocarcinoma and hepatocellular carci-
noma; incidence 7.7; Source: National Statistical
Office of Switzerland; available online: http://www.
bfs.admin.ch) and liver metastases of colon-carcinoma
(incidence of metastasis of 10 [31]).
2. Differential diagnosis of CE from liver cysts (Swiss
patients). CE in Swiss patients presenting with cystic
liver lesions in imaging studies was estimated at 1% on
the basis of figures available for the University
Hospital Zu¨rich [abdominal US, chest computed
tomography (CT), chest X-rays: 200,000 per year,
CE cases: 2–5 per year; KB, personal communication].
3. The annual incidences (2001–2005) of probable or
confirmed AE cases in Switzerland were 0.26 [6]. As it
is known from animal experiments that serological test
scores are positive as early as 4–8 weeks post-infec-
tion [32] and due to the long asymptomatic period of
5–15 years in AE [2, 3], the given incidence would not
reflect the prevalence of cases that would become
clinically relevant within the following 15 years but
which already score positive in the serological screen-
ing. Thus, the annual incidences were multiplied by 15
as a rough estimate of the actual prevalence of
asymptomatic individuals who are already infected,
adding up to a prevalence of 0.042% in all of
Switzerland.
As no further clinical data were known and no studies on
the sensitivity/specificity of differentiating AE or CE from
their most common differential diagnoses based on imaging
study results were available, the prevalences specified above
were used as pre-test probabilities for further calculations.
Statistical analyses
Statistical analysis and ROC were performed in SPSS ver.
17.0 (SPSS, Chicago, IL).
Binomial confidence intervals for sensitivity, specificity
and predictive values were calculated according to the
Clopper and Pearson method. The McNemar test for
associated binominal values was used to calculate signifi-
cance within patient groups (e.g. comparison of sensitivity
for AE in separate antigens).
Results
Diagnostic performance: sensitivities of single tests
The sensitivities of the tests [with 95% confidence inter-
vals (CIs)] for the serological diagnosis of either AE or CE
were calculated for all antigens and are summarised in
Table 2.
All crude or partially purified antigens had very high
sensitivities in testing for AE (C99.9%, 95% CI
94.3–100%) regardless of the parasite species they had
been prepared from. The results were not significantly
different from those of the most widely used standard
EgHF-ELISA. AgB, Em2(G11) and the Em18 antigen
detected C99.9 (95% CI 94.3–100), 88.2 (95% CI
76.1–95.6) and 92.2% (95% CI 81.1–97.8%) of the cases,
respectively (differences not significant).
Sensitivities of the crude or partially purified antigens
for CE ranged from 81.3 (95% CI 63.6–92.8, EmVF) to
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96.9% (95% CI 83.8–99.9%; EgP). AgB used in ELISA
had a sensitivity of 93.8% (95% CI 79.2–99.2%). Again,
the differences were statistically not significant, when
compared to the those of the EgHF-ELISA. AgB-EITB
had a sensitivity of 62.7 (95% CI 48.1–75.9) and 78.1%
(95% CI 60.0–90.7%) for the diagnosis of AE and CE,
respectively.
Of the seven CE patients without hepatic involvement,
only one patient with an isolated lesion in the omentum
would have been missed (EgPI-ELISA). False negative
reactions in cases with liver involvement occurred in two
inactive or transitional stage cysts and one active stage cyst
with the use of EgPI (CE3: 1/5; CE5: 1/3; CE3: 1/5; CE1:
1/4) and four inactive or transitional stage cysts with the
use of AgB-EITB (CE3: 3/5; CE5: 1/3). However, no
significant difference was found. In two patients scoring
false negative when EgHF, EgP, EgPI and AgB-ELISA,
respectively, were used, the cyst stage could not be
evaluated.
Diagnostic performance: species-specific diagnosis
and confirmatory testing
With the exception of the purified Em2(G11) and recom-
binant Em18 antigen, all antigens tested reacted with serum
antibodies from most AE and CE patients and therefore did
not allow for a species-specific serological diagnosis. In the
ELISA based on the most species-specific antigens
[Em18 and Em2(G11)], positive reactions with antibodies
in the serum samples from CE patients in the range of 6.3%
(0.8–20.8%) and 18.8% (7.2–36.4%), respectively, were
recorded. The combined sensitivity for AE of both tests
(positive was defined as a patient scoring positive in either
test) was 98.0 (range 89.6–100.0) with cross-reactions to
CE in the range of 18.8% (7.2–36.4%). As all crude or
partially purified antigens reached sensitivities of [99.9%
in our evaluation, the sensitivities and values for the cross-
reacting CE sera of the Em2(G11)- and Em18-based tests
also represent the diagnostic performance of combined
testing for AE with the use of one of these two antigens in a
confirmatory test. The diagnosis of CE with confirmation
by AgB-EITB reached sensitivities ranging from 68.8
(95% CI 50.0–83.9; EgPI) to 75% (95% CI 56.6–88.5%;
several antigens) (see Table 2). With respect to the local-
isation and cyst stages, AgB-EITB failed to recognise one
patient with a bone lesion, three patients suffering from
CE3 and one patient with type CE5 cysts.
Diagnostic performance: specificity and cross-reactions
Specificities were calculated for 38 patients with non-
parasitic liver lesions from Switzerland, 80 patients with
other parasitic infections and 98 Swiss blood donors
(Table 2). Specificities estimated for patients with non-
parasitic liver lesions were excellent, ranging from 92.1
(95% CI 78.6–98.3; AgB-ELISA) to [99.9% (95% CI
92.4–100%). Differences, when compared to the results
of the standard EgHF-ELISA, were not significant.
Specificities for the AgB-EITB, the Em2G11- and Em18-
ELISA were [99.9% (92.4–100%) for patients with
non-parasitic liver lesions.
Cross-reactions with antibodies in sera of 80 patients
suffering from different other parasitic infections were
found at varying extents in all antigens and are summarised
in Table 3. Among the crude or partially purified antigens,
the EgPI antigen proved to be most specific (13 false
positive reactions). The most common cross-reactions were
recorded with antibodies present in the sera of cysticercosis
and fasciolosis patients. However, tests based on the spe-
cies-specific antigens Em2(G11) and Em18 gave no false
positive reactions for these two patient groups. Hardly any
cross-reactions with antibodies in the sera of patients with
amoebic liver abscesses were recorded. Only one cross-
reaction with amoebic liver abscess was recorded for the
recombinant Em18 antigen, and the Em2G11 and AgB-
EITB antigens exhibited no cross-reactions at all.
Table 3 Cross-reactions to antibodies in sera of patients suffering from selected parasitic infections
Parasitic disease Number of false positive reactions AgB-EITB
EgHF EgP EgPI AgB EmC EmP EmPI EmVF Em2(G11) Em18
Amebosis (n = 19) 0 0 0 1 6 0 1 0 0 1 0
Cysticercosis (n = 19) 11 13 7 9 10 14 12 14 0 0 0
Fasciolosis (n = 16) 6 4 2 8 10 10 3 10 0 0 0
Filarioses (n = 8) 2 2 2 5 8b 5 3 5 0 0 0
Schistosomosis (n = 18) 4 2 2 4 7 2 2 2 0 0 0
Total (n = 80) 23 21 13b 27 41b 31 21 31 0a,b 1a,b 0a,b
a Significantly fewer cross-reactions compared to all other antigens (McNemar test)
b Significant difference in number of cross-reactions compared to EgHF as the gold standard (McNemar test)
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Diagnostic performance: likelihood ratios and post-test
probabilities
Positive and negative likelihood ratios and eventually post-
test probabilities (PTPs) were calculated for different
clinical and epidemiological settings as described in the
‘‘Materials and methods’’. Negative likelihood ratios for all
antigens in terms of AE or CE diagnosis were\0.02. Thus,
negative PTPs were determined to be \0.01% in the dif-
ferential diagnosis and screening in all cases (data not
shown). Likelihood ratios and positive PTPs are summa-
rised in Table 4. For the differential diagnosis of the most
common liver neoplasias in Switzerland relative to AE,
positive PTPs ranged from 20.0 (95% CI 11.7–20.0, AgB-
ELISA) to 95.2% (95% CI 90.8–95.2%, in several
antigens). With the application of confirmatory testing,
positive PTPs for Em2G11, Em18 and the combination of
both tests were 94.6 (95% CI 89.7–94.6), 94.8 (95% CI
90.1–94.8) and 95.1% (95% CI 90.7–95.1%), respectively,
without significant differences. The differential diagnosis
of cystic lesions compared to CE by the use of E. granu-
losus-derived antigens in Switzerland showed positive
PTPs ranging from 9.2 (95% CI 5.3–9.2, AgB) to 89.2%
(95% CI 80.5–89.2%; EgP). Positive PTPs for AE
screening in Switzerland ranged from 0.1 (95% CI
\0.1–0.1, EgHF) to 2.2% (95% CI 1.1–2.2%; EmPI,
Em18).
Impact of different preparation-techniques
Pearson correlation coefficients for OD405 values were
calculated for antigens derived from different morpholog-
ical correlates (EmC vs. EmP: 0.774; EmC vs. EmVF, EmP
vs. EmPI: 0.893; EgP vs. EgPI: 0.822), and all evaluated
pairs were significantly correlated.
The cyst/Em2-depleted protoscolex antigen (EmP)-
based assay showed significantly fewer cross-reactions (19/
80) than a crude metacestode antigen (EmC, 41/80)-based
test (p = 0.05, McNemar test). On the other hand, prepa-
ration of the integument antigen (EmPI) compared to
whole protoscolex antigen (EmP) did not significantly
change the results. Isolation of E. multilocularis cyst fluid
(EmVF) as compared to the whole metacestode antigen
(EmC) yielded only a trend in fewer cross-reactions (31/80
and 41/80, respectively, p = 0.08).
Among the E. granulosus-derived antigens, no differ-
ence was found between EgHF and EgP, whereas prepa-
ration of the integument (EgPI) as compared to whole
Table 4 Likelihood ratios and post-test probabilities for serological diagnosis of AE or CE
Antigen Positive likelihood ratiosa Post-test probabilities (%)
Alveolar
echinococcosis
Cystic
echinococcosis
Setting A:
differential diagnosis
of AE from liver
neoplasias (pre-test
probability = 1.5%)b
Setting B: differential diagnosis
of CE from cystic liver lesions (pre-
test probability = 1%)b
Setting C:
screening for AE
in Switzerland
(pre-test
probability
= 0.04%)c
Single test With confirmatory
test (AgB-EITB)
EgHF 51.0 (51.0–26.0) 30.0 (30.0–15.5) 42.9 (27.7–42.9) 23.3 (13.5–23.3) 86.45 (86.4–76.2) 0.1 (0.0–0.1)
EgP 1,342.1 (1342.1–671.6) 815.8 (815.8–408.4) 95.2 (90.8–95.2) 89.2 (80.5–89.2) 86.45 (86.4–76.2) 0.2 (0.1–0.2)
EgPI 1,342.1 (1342.1–671.6) 684.2 (684.2–342.6) 95.2 (90.8–95.2) 87.4 (77.6–87.4) 85.40 (85.4–74.5) 0.2 (0.1–0.2)
AgB 17.0 (17.0–9.0) 10.0 (10.0–5.5) 20.0 (11.7–20.0) 9.2 (5.3–9.2) n/a 0.1 (0.0–0.1)
EmC 1,342.1 (1342.1–671.6) 763.2 (763.2–382.1) 95.2 (90.8–95.2) n/a n/a 0.1 (0.0–0.1)
EmVF 51.0 (51.0–26.0) 30.0 (30.0–15.5) 42.9 (27.7–42.9) n/a n/a 0.1 (0.0–0.1)
EmP 1,342.1 (1342.1–671.6) 763.2 (763.2–382.1) 95.2 (90.8–95.2) n/a n/a 2.2 (1.1–2.2)
EmPI 1,342.1 (1342.1–671.6) 710.5 (710.5–355.8) 95.2 (90.8–95.2) n/a n/a 2.2 (1.1–2.2)
Em18 1,236.8 (1236.8–618.9) n/a 94.8 (90.1–94.8) n/a n/a 2.0 (1.0–2.0)
Em2G11 1,184.2 (1184.2–592.6) n/a 94.6 (89.7–94.6) n/a n/a 1.9 (1.0–1.9)
AgB-
EITB
1,342.1 (1342.1–671.6) 657.9 (657.9–329.4) 95.2 (90.8–95.2) 39.7 (24.8–39.7) n/a
AE Alveolar echinococcosis, CE cystic echinococcosis
Negative post-test probabilities are not included, as they are all\0.01% without significant differences. Post-test probabilities for confirmatory
testing of AE cases are not shown as they are equal to the corresponding values of the confirmatory antigens. Negative likelihood ratios for AE
(all antigens) were \0.0 (0.0–0.1) and those for CE were \0.0 (0.0–0.1) to 0.2 (0.1–0.3)
a Sensitivities and specificities of 99.9% were used for the calculation of likelihood ratios
b Specificity of sera from patients suffering from non-parasitic liver diseases was used for the calculation
c Specificity of sera from Swiss blood donors was used for the calculation
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protoscolex antigen (EgP) had overall fewer cross-reac-
tions (13/80 and 21/80, respectively; p \ 0.005), especially
for cysticercosis (7/19 and 13/19, respectively; p = 0.03).
Unfortunately a trend towards a lower sensitivity for CE
was noted in EgPI (81.3%; EgP: 96.9%; p = 0.06).
Discussion
The aim of this study was to compare the diagnostic per-
formances of crude and partially purified native Echino-
coccus antigens that are easy to produce and to assess their
value in defined clinical and epidemiological settings.
Typical situations in which specific anti-Echinococcus
antibodies are determined are the differential diagnosis of
AE and CE from other cystic- or tumour-like pathologies
and epidemiological surveillance programmes. Therefore,
treatment-naı¨ve AE and CE-patients, patients with other
types of liver pathologies as well as a screening situation in
a low endemic area were included in the evaluation.
The most commonly used tests for the diagnosis of CE
are based on hydatid fluid antigens of E. granulosus. These
tests have relatively high sensitivities for hepatic (85–95%)
and multiple organ cysts (90–100%), but lower sensitivities
for lung cysts (50–60%) [33–35]. Additionally, tests based
on the partially purified lipoproteins antigen B (AgB) and
antigen 5 (both found in the germinal membrane, protos-
colex parenchyma and cyst fluid [36]) are used either in
ELISA or immunoblot assays. The major drawback of
these tests is the lack of species specificity, as cross-reac-
tions between AE and CE and many other helminthic
infections are commonly observed (cestodes, 89%; nema-
todes, 39%; trematodes; 30%) [5, 20, 37–40]. Assays based
on a recombinant subunit of AgB, denoted rAgB8/2,
showed sensitivities of 45–93% and specificities of
86–99% with the same cross-reactions as mentioned above
[20, 41, 42].
In our study, all non-AE-derived native or partially
purified antigens exhibited sensitivities ranging from 81.3
to 96.9% for the diagnosis of CE; as such, they are not
significantly different from antigen preparations that are
currently available. As only seven of the 32 CE patients
evaluated had no hepatic involvement in our study, no
sound conclusions on test performances in cases with
extrahepatic lesions can be drawn. Additionally, cysts of
morphology type CL, based on the WHO classification
system, cannot be distinguished from hepatic cysts of other
origins by US, and differential diagnosis in these cases is
especially difficult [21]. Unfortunately, no patients with
cysts of this type were available for the study. Thus, the
relatively high sensitivities for CE may be biased by
the panel of sera used and may not be extrapolated for the
serological diagnosis of these types of lesions.
Different antigen preparations are in use for the sero-
logical diagnosis of AE. The most commonly used tests,
although not species specific, are also ELISA based on
E. granulosus hydatid fluid (EgHF) and have sensitivities
ranging from 90 to 97% for AE [40]. For the detection of
AE cases, the native antigens tested in our study, regardless
of the species they were derived from, proved to be well
suited, as all cases were detected by all tests. Our antigens
exhibited high sensitivities of [99% for the diagnosis of
AE, but species specificity was lacking.
For species-specific serological diagnosis, recombinant
E. multilocularis antigens (such as II/3-10, Em10- or
Em18-antigen; all of which belong to the same protein
family), either alone or in the form of the Em2Plus ELISA
(Bordier Affinity Products, Crissier, Switzerland) as a
combination of the II/3-10 and Em2 antigens, are com-
monly used. These antigens have diagnostic sensitivities
ranging between 81 and 100% and discriminate between
AE and CE with a reliability ranging from 80 to C95% [15,
26, 27, 43–46]. The native and partially purified antigens
tested in our study did not discriminate between AE and
CE: they all recognised all AE and at least 81.3% of CE
cases. As already well-established, only the Em2G11- and
Em18-antigens in our antigen panel differentiated AE from
CE in 81.3 and 93.7% of cases, respectively, thereby pro-
viding tools for species differentiation.
The various AgB-ELISA that are in use for the diagnosis
of either CE or AE have been found to have different
sensitivities. Mamuti and colleagues [47] used a recombi-
nant AgB8/1, reporting sensitivities of 88.0% (95% CI
75.7–95.5%) for CE and 37.8% (95% CI 23.7–53.5%) for
AE. In another study by Li and colleagues [48], a recom-
binant AgB subunit 8, basically prepared as described by
Mamuti and colleagues [47], reached sensitivities of 77.6%
(95% CI 77.6–82.7%) for CE and 85.0% (95% CI
78.8–89.9%) for AE; in terms of AE, this is significantly
more sensitive than that reached by Mamuti and colleagues
with the recombinant AgB8/1, but not more sensitive than
that found in our study using native AgB ([99.9%; 95% CI
94.3–100%). Sensitivities for CE did not differ signifi-
cantly between all three studies and were comparable with
the results of a study by Gihan and colleagues [49] where a
sensitivity of 82.5% (95% CI 73.2–95.8%) was reported.
The differences in the sensitivities for AE are likely to be
explained as being related to the different panels of sera
used. Whereas Mamuti and colleagues evaluated sera from
patients under treatment or post-surgery, in the study by Li
and colleagues and in our study only sera from treatment-
naı¨ve patients were used, leading to distinctly higher
sensitivities.
The parallel use of multiple native antigens (EgHF, EgP,
AgB and Em2) in a dot–immunogold filtration assay
(DIGFA) analysing patients with probable or confirmed CE
Serological diagnosis of echinococcosis 147
123
or AE yielded sensitivities for CE and AE of 80.7 and
92.9%, respectively, with a specificity of 89.6% [50]. The
isolated analysis of the AgB-dot had a sensitivity and
specificity for CE of 68.4 and 93.4%, respectively, whereas
the isolated analysis of the Em2-dot diagnosed 83.3% of
AE patients with a specificity of 90.3% and reliability for
species differentiation of 83.0% [50]. Although the overall
performances of these tests were lower than those in our
study, differences in the epidemiological background and
serum panel used have to be taken into account.
Test specificities were excellent for most of our antigens
when Swiss patients with non-parasitic liver lesions were
tested. False positive reactions were only recorded for the
AgB-, EgHF- and EmVF-based ELISA. The application of
our confirmatory tests subsequently removed all of these
false-positive reactions, as these tests have specificities
[99.9%. Except for the Em2(G11) and the Em18 antigen,
all antigens used in the ELISA showed a substantial
number of cross-reactions, mainly with antibodies in sera
of patients suffering from cysticercosis and fasciolosis,
although the intensity of the serological reactions (given in
Fig. 1) varied. However, cut-off-values could be adapted
for certain antigens (mainly EmP, EmVF) to maintain a
high sensitivity for AE while minimising the number of
cross-reactions (data not shown). Nevertheless, additional
evaluations by confirmatory testing and imaging studies
should be performed. Fasciolosis in the hepatic stage can
be differentiated by clinical symptoms and typical radio-
logical signs, such as clustered hepatic micro-abscesses in a
serpentine-fashion or the ‘‘tunnels-and-caves-sign’’ [51,
52]. In addition, species-specific tests based on excretory/
secretory-proteins of Fasciola sp. allow discrimination by
serology—for example, by the Fas2-ELISA [53]. Further
diagnosis could be achieved by coproscopy, i.e., demon-
strating eggs of the parasite in stool samples [52, 54]. For
the differential diagnosis of cysticercosis, a highly specific
western blot based on Taenia solium-derived glycoproteins
and an ELISA based on recombinant antigens are available
[55, 56], although in EITB cross reactivity with sera from
AE patients with non-diagnostic higher molecular weight
components have been reported [57]. Schistosomosis in
imaging studies mainly appears in the periportal tissue
together with fibrosis, calcification (mainly in Schistosoma
japonicum, rare in S. mansoni) and thickening of the walls
of periportal septae and the liver capsule [58], features
usually not seen in Echinococcus patients. Diagnosis is
usually achieved by the detection of the parasite’s eggs in
stool or urine, except for the acute phase, which is clini-
cally very distinct from echinococcosis [59]. Thus, other
parasitic diseases with manifestation in the liver can be
distinguished by means of the clinical presentation, direct
detection of parasite’s eggs, serology and radiology. In
addition, by the application of confirmatory tests, all but
one cross-reaction to antibodies in the serum of a patient
suffering of amoebic liver abscess (initial test: EmC-
ELISA; confirmation test: Em18-ELISA) were prevented.
Despite rising incidences in many regions, AE and CE
prevalences are still low compared to other hepatic affec-
tions such as liver cysts or hepatic neoplasias [60]. Thus, it
is crucial in practical clinical work to be able to estimate
the probability that a patient is suffering from AE or CE
once the serological test results are known. The calculation
of positive or negative PTPs in a given patient or collective
patients using likelihood ratios that are based on test sen-
sitivities and specificities, together with the use of the pre-
test probability as an estimator that integrates the preva-
lence of a disease among the people tested and additional
clinical and radiological information, is one of the best
tools for this task [30].
In the case of screening campaigns, only the anticipated
prevalence is determined—no further information on the
people tested is known. Therefore, the pre-test probability
is low and essentially in accordance with AE or CE prev-
alence. Hence, PTPs are low in such settings. In the Swiss
example (screening for AE), the positive PTPs are\0.1%,
and they do not improve considerably with the application
of confirmatory tests (\2.2%). In contrast, the corre-
sponding negative PTPs are all \0.01; consequently, they
allow an infection to be excluded with a high probability.
However, a substantial number of patients might be missed
in large screening programmes, as has been outlined by
Torgerson and Deplazes [61]. This clearly underlines the
necessity of additional examination techniques (i.e. imag-
ing techniques) to identify and confirm cases in such set-
tings. A drawback of our assumption is the fact that the
number of patients with died-out lesions is hard to esti-
mate. Therefore, these patients could not be included in the
estimated prevalence. However, patients prone to develop
clinically relevant disease within 0–15 years post-screen-
ing were covered. Thus, the estimated prevalence may not
exactly depict the prevalence, but the dimension is appro-
priately covered.
In contrast, in defined clinical settings where highly
preselected patients based on clinical and radiological
information are tested, CE and AE prevalences are sub-
stantially higher than those found in the general population.
The same may be true for combined radiological and
serological screening programmes. The estimated preva-
lence of AE lesions among Swiss patients with suspicion of
liver neoplasias undergoing imaging examinations was
1.5%, and this value was taken as the pre-test probability.
Therefore, positive PTPs of all tests in combination with
confirmatory testing were [94.6%. The estimated CE
prevalence among patients at the University Hospital of
Zurich with cystic liver lesions was 1%. In this clinical
setting, positive PTPs of the tests based on E. granulosus-
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Fig. 1 Intensity of serological reaction (OD405) to defined patient
groups of different metacestode-derived antigens of Echinococcus
granulosus (a) and E. multilocularis (b) in comparison to the species-
specific confirmatory antigens Em18 and Em2G11 (c). AE Alveolar
echinococcosis, CE cystic echinococcosis, NPLD non-parasitic liver
disease. See Table 1 for definitions of antigens
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derived antigens ranged from 9.2 (AgB-ELISA) to 89.2%
(EgP). The AgB-EITB test results for confirming these
values were around 87% for all tests. In both settings,
serology contributed substantially to ascertain the definite
diagnosis.
Other diagnostic evaluations and clinical presentations
will contribute to the pre-test-probabilities and therefore
significantly change PTPs. Several cyst stages in CE have
pathognomonic radiological signs [21]. In AE, specific
radiological features, such as the lack of perilesional
enhancement as compared to neoplasias [62], will restrict
differential diagnoses and therefore influence pre-test and
subsequently PTPs in a positive or negative way. For
example, if the differentiation of CE from other cystic liver
lesions were possible with a probability of 75%, positive
PTPs for CE would increase to [95% after serological
diagnosis with EgPI as compared to 87% when only
prevalence is used. However, one has to be aware that even
minor changes in the specificity of any test will result in a
considerable change in the PTP.
Depletion of Em2 and adhering cyst-material in E. mul-
tilocularis-derived antigens (EmP, EmPI) neither reduced
the number of cross-reactions with antibodies in sera from
patients suffering from other parasitic infections nor
improved test sensitivities or specificities. Also, the isola-
tion of integument antigens (EgPI; EmPI) as compared to
whole protoscolex antigens (EgP; EmP) had no significant
impact on the diagnostic performances, although cross-
reactions were significantly lower in the EgPI-based assay.
The same holds true for the purification of protoscoleces of
E. multilocularis as compared to crude metacestode-
derived antigens (EmC), where the number of cross-reac-
tions could be significantly decreased.
In conclusion, different easy-to-prepare and inexpensive
metacestode-derived native antigens of E. multilocularis
and E. granulosus are valuable tools for the diagnosis of
CE and AE in clinical settings. Negative results in any of
these tests rule out AE cases with a high certainty, and due
to the high sensitivities, hardly any clinical cases would be
missed. As only a limited number of inactive CE cases or
cases with isolated lung cysts were available for this study,
the same conclusion might not automatically apply for CE
patients.
Based on the tests evaluated here, an efficient approach
to the serological diagnosis of echninococcosis is primary
testing with the crude E. granulosus protoscolex-derived
antigen (EgP) alone or in combination with EgHF, fol-
lowed by the additional testing of positive cases with
species-specific antigens Em18 and Em2G11 for differen-
tial diagnosis at species level and confirmation of AE. Sera
testing negative in the AE-specific tests are suspicious for
CE and should be confirmed by, for example, AgB-EITB.
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